TCT Session. An assessment of the severity of lesions. A debate about the different methods to assess coronary physiology.

FFR is the gold standard (Dr. William Fearon)

Dr. William reported on the benefits of using FFR: 

• A high degree of accuracy in identifying lesions that cause ischemia.

• It allows you to specify angioplasty safely.

• It improves results when compared to standard practice.

• It is technically safe, easy to perform, economical and thus provides higher profitability.

It is considered that a FFR of <0.75 ensures a sensitivity of 88% and a specificity of 100%, highly reproductive technique as demonstrated in comparative studies and a small error margin, (small range of gray area). The FAME study showed after one year, better evolution of angioplasties that were guided by FFR and not only by angiography.

Instantaneous wave-free ratio (iFR) validation studies (Dr. Justin Davies) 

Dr. Justin showed in his lecture that iFR is a method that has the same precision and power to detect significant ischemia as FFR compared to other diagnostic modalities. Evaluations with iFR can be done in real time and without causing hyperemia which obviously offers practical advantages. This is a great advantage of iFR versus FFR, since there is no need to inject adenosine.

What is the FFR (CT)? Is it ready to be used? (Dr. Koo Bon Kwon)

This new method offers the advantage of integrating an imaging method for the non-invasive assessment of coronary physiology. The FFR (CT) can predict the functional importance of injury while helping plan the treatment strategy when the patient undergoes the procedure. Dr. Koo also notes that new technologies and studies are needed to complete the integration of this new approach to evaluating coronaries.

2013-03-09

More articles by this author

TCT Session

Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor because of the high profile of the...

PREVAIL: LAA occlusion versus anticoagulation with warfarin to prevent stroke in patients with non-valvular atrial fibrillation.

An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release of the study results. Due to an...

THRIVE: Niacin/laropiprant extended release showed no significant cardiovascular benefit.

The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis that the increase in HDL, (using ER...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....